Cover Image
Market Research Report

Cervical Cancer- Market Insight, Epidemiology and Market Forecast -2030

Published by DelveInsight Business Research LLP Product code 963733
Published Content info 174 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cervical Cancer- Market Insight, Epidemiology and Market Forecast -2030
Published: October 14, 2020 Content info: 174 Pages
Description

DelveInsight's 'Cervical Cancer -Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Cervical Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Cervical Cancer market report provides analysis regarding current treatment practices, emerging drugs like Cemiplimab, Durvalumab, LN-145, Z-100, Tisotumab vedotin, promising therapies, market share of the individual therapies, and historical, current and forecasted Cervical Cancer market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Cervical Cancer treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Cervical Cancer - Disease Understanding and Treatment Algorithm

Overview:

Cervical cancer is one of the most common gynecological tumors that occur in the cells of the cervix. The most significant cause of cervical cancer is persistent papillomavirus infection. Gynecological cancers are among the most common cancers in women. Cervical cancer is the most common type of gynecological cancer. Indeed, it is one of the major public health problems in the world and one of the top causes for disability-adjusted life-years (DALYs). Yet, cervical cancer is one of the most preventable cancers. HPV is the most common sexually transmitted infection worldwide and is the cause of almost all cases of cervical cancer. Because precancerous lesions can be found by the Papanicolaou (Pap) test and treated and cured, cervical cancer is often detected before it becomes advanced.

Treatment:

The standard management of patients with early-stage (FIGO stage IA-IB1) cervical cancer is a radical hysterectomy and lymph node dissection and/or radiation with or without chemotherapy. The standard management of individuals with locally advanced cervical cancer includes external beam radiotherapy with concurrent cisplatin-based chemotherapy with brachytherapy.

This chapter covers the details of conventional and current medical therapies available for the treatment of Cervical Cancer. It also provides Cervical Cancer treatment guidelines across the United States, Europe, and Japan.

DelveInsight's Cervical Cancer market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Cervical Cancer treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Epidemiology:

The Cervical Cancer epidemiology chapters provide insights about historical and current Cervical Cancer patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Cervical Cancer epidemiology is segmented by the Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer. Besides, the report includes a thorough analysis of all segments.

According to DelveInsight's , the total prevalent population of Cervical Cancer in seven major markets was 43,514 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, total prevalent cases for Cervical Cancer were highest in the United States, followed by Japan and Germany. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Cervical Cancer pipeline. It also helps understand the cervical cancer clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Therapies administered for treatment of metastatic or recurrent cases comprises systemic therapies, which include paclitaxel plus cisplatin-based doublets or triplet combination therapies. Over the past three decades, these have remained the mainstay or standard of care (SOC) without vastly impacting the median overall survival (OS) of patients with stage IVB or recurrent disease despite multiple studies with single-agent or combination chemotherapy. FDA approved drugs include Avastin, Keytruda and Hycamtin.

Market Outlook:

The market size of Cervical Cancer is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Cervical Cancer market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 25.46 million, while Spain had the smallest market size of USD 0.34 million.

Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Cervical Cancer market or expected to get launched in the market during the study period 2017-2030. The analysis covers Cervical Cancer market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) are the major players that are going to alter the market dynamics in the coming years, during the forecasted period 2020-2030.

Cervical Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Cervical Cancer .

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Cervical Cancer domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Cervical Cancer Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights::

  • In the coming years, Cervical Cancer market scenario is expected to experience a positive shift across the 7MM due a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Cervical Cancer Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Cervical Cancer Pipeline Analysis
  • Cervical Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cervical Cancer Report Key Strengths:

  • 11 years Forecast
  • 7MM Coverage
  • Cervical Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Cervical Cancer Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Cervical Cancer market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Cervical Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Cervical Cancer market size during the forecast period (2017-2030)?
  • At what CAGR, the Cervical Cancer market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Cervical Cancer market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Cervical Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Cervical Cancer?
  • What is the historical Cervical Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cervical Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Cervical Cancer?
  • Out of all 7MM countries, which country would have the highest prevalent population of Cervical Cancer during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Cervical Cancer treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cervical Cancer in the USA, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Cervical Cancer?
  • How many therapies are developed by each company for Cervical Cancer?
  • How many are emerging therapies in mid-stage, and late stage of development for Cervical Cancer treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cervical Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cervical Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for Cervical Cancer?
  • What is the global historical and forecasted market of Cervical Cancer?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Cervical Cancer market
  • To understand the future market competition in the Cervical Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cervical Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cervical Cancer market
  • To understand the future market competition in the Cervical Cancer market

Which geography accounted for the largest Cervical Cancer market size?

The United States accounted for the largest Cervical Cancer market size.

What is forecasted Cervical Cancer size in 2030?

DelveInsight estimates an increase in Cervical Cancer Market Size during the study period, 2017-2030

What are the present Cervical Cancer market drivers?

Advancements in treatment, improvement in preventive measures, early detection of disease, therapies in development for recurrent and relapsed cases,

What are the Cervical Cancer market barriers?

Insufficient data on disease biomarkers, barriers in screening, access to palliative care, costs associated with treatment

How many companies are developing drugs for Cervical Cancer?

Currently, six key pharma players are developing the drug for Cervical Cancer

Which are the leading companies in Cervical Cancer market?

Key Players - Regeneron, AstraZeneca, LN-145, Zeria Pharmaceutical, Seattle Genetics/Genmab, Advaxis

How is epidemiology segmented for Cervical Cancer?

Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer

Table of Contents

Table of Contents

1 Key Insights

2 Executive Summary of Cervical Cancer

3 SWOT Analysis for Cervical Cancer

4 Cervical Cancer Epidemiology Overview at a Glance

  • 4.1 Patient Share (%) Distribution of Cervical Cancer in 2017
  • 4.2 Patient Share (%) Distribution of Cervical Cancer in 2030

5 Cervical Cancer Market Overview at a Glance

  • 5.1 Market Share (%) Distribution of Cervical Cancer in 2017
  • 5.2 Market Share (%) Distribution of Cervical Cancer in 2030

6 Disease Background and Overview

  • 6.1 Introduction
  • 6.2 Definition
  • 6.3 Etiology
  • 6.4 Risk factors
  • 6.5 Staging
  • 6.6 Pathophysiology
  • 6.7 Diagnosis

Forty-year timeline of public health research and policy on HPV and cervical cancer

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Total Incident Population of Cervical Cancer in 7MM
  • 7.3 Assumption and Rationale: 7MM

8 Country Wise-Epidemiology of Cervical Cancer

  • 8.1 The United States
    • 8.1.1 Incident cases of Cervical Cancer in the United States
    • 8.1.2 Stage-specific Incidence of Cervical Cancer in the United States
    • 8.1.3 Histopathologic Types of Cervical Cancer in the United States
    • 8.1.4 Age-specific cases of Cervical Cancer in the United States
  • 8.2 Germany
    • 8.2.1 Incident cases of Cervical Cancer in Germany
    • 8.2.2 Stage-specific Incidence of Cervical Cancer in Germany
    • 8.2.3 Histopathologic Types of Cervical Cancer in Germany
    • 8.2.4 Age-specific cases of Cervical Cancer in Germany
  • 8.3 France
    • 8.3.1 Incident cases of Cervical Cancer in France
    • 8.3.2 Stage-specific Incidence of Cervical Cancer in France
    • 8.3.3 Histopathologic Types of Cervical Cancer in France
    • 8.3.4 Age-specific cases of Cervical Cancer in France
  • 8.4 Italy
    • 8.4.1 Incident cases of Cervical Cancer in Italy
    • 8.4.2 Stage-specific Incidence of Cervical Cancer in Italy
    • 8.4.3 Histopathologic Types of Cervical Cancer in Italy
    • 8.4.4 Age-specific cases of Cervical Cancer in Italy
  • 8.5 Spain
    • 8.5.1 Incident cases of Cervical Cancer in Spain
    • 8.5.2 Stage-specific Incidence of Cervical Cancer in Spain
    • 8.5.3 Histopathologic Types of Cervical Cancer in Spain
    • 8.5.4 Age-specific cases of Cervical Cancer in Spain
  • 8.6 The United Kingdom
    • 8.6.1 Incident cases of Cervical Cancer in the United Kingdom
    • 8.6.2 Stage-specific Incidence of Cervical Cancer in the United Kingdom
    • 8.6.3 Histopathologic Types of Cervical Cancer in the United Kingdom
    • 8.6.4 Age-specific cases of Cervical Cancer in the United Kingdom
  • 8.7 Japan
    • 8.7.1 Incident cases of Cervical Cancer in Japan
    • 8.7.2 Stage-specific Incidence of Cervical Cancer in Japan
    • 8.7.3 Histopathologic Types of Cervical Cancer in Japan
    • 8.7.4 Age-specific cases of Cervical Cancer in Japan

9 Treatment and Management

  • 9.1 Side effects of treatment
  • 9.2 Prevention of Cervical cancer
  • 9.3 Guidelines
    • 9.3.1 NCCN Guidelines
    • 9.3.2 ESMO guidelines
    • 9.3.3 Japan Society of Gynecologic Oncology (JSGO) Guidelines
  • 9.4 Patient Journey

10 Unmet Needs

11 Marketed Therapies

  • 11.1 Avastin (Bevacizumab): Genentech/Roche
    • 11.1.1 Product Description
    • 11.1.2 Regulatory Milestones
    • 11.1.3 Other developmental activities
    • 11.1.4 Clinical Development
      • 11.1.4.1 Clinical Trials Information
    • 11.1.5 Safety and Efficacy
    • 11.1.6 Product Profile
  • 11.2 Avastin Biosimilars
    • 11.2.1 Mvasi: Amgen/Allergan
      • 11.2.1.1 Product Description
      • 11.2.1.2 Regulatory Milestones
      • 11.2.1.3 Other developmental activities
    • 11.2.2 Zirabev: Pfizer
      • 11.2.2.1 Product Description
      • 11.2.2.2 Regulatory Milestones
    • 11.2.3 Aybintio: Samsung Bioepis
      • 11.2.3.1 Product Description
      • 11.2.3.2 Regulatory Milestones
  • 11.3 Hycamtin (Topotecan Hydrochloride): GlaxoSmithKline/Novartis
    • 11.3.1 Product Description
    • 11.3.2 Regulatory Milestones
    • 11.3.3 Other developmental activities
    • 11.3.4 Clinical Development
      • 11.3.4.1 Clinical Trials Information
    • 11.3.5 Safety and Efficacy
    • 11.3.6 Product Profile
  • 11.4 Keytruda (Pembrolizumab): Merck Sharp & Dohme
    • 11.4.1 Product Description
    • 11.4.2 Regulatory Milestones
    • 11.4.3 Clinical Development
      • 11.4.3.1 Clinical Trials Information
    • 11.4.4 Safety and Efficacy
    • 11.4.5 Product Profile

12 Emerging Therapies

  • 12.1 Tisotumab vedotin: Seattle Genetics/ Genmab
    • 12.1.1 Product Description
    • 12.1.2 Product Development Activities
    • 12.1.3 Clinical Development
      • 12.1.3.1 Clinical Trial Information
    • 12.1.4 Safety and Efficacy
  • 12.2 Durvalumab: AstraZeneca
    • 12.2.1 Product Description
    • 12.2.2 Product Development Activities
    • 12.2.3 Clinical Development
      • 12.2.3.1 Clinical Trial Information
  • 12.3 Z-100: Zeria Pharmaceutical
    • 12.3.1 Product Description
    • 12.3.2 Clinical Development
      • 12.3.2.1 Clinical Trial Information
    • 12.3.3 Safety and Efficacy
  • 12.4 Cemiplimab: Regeneron Pharmaceutical/Sanofi
    • 12.4.1 Product Description
    • 12.4.2 Product Development Activities
    • 12.4.3 Clinical Development
      • 12.4.3.1 Clinical Trial Information
    • 12.4.4 Safety and Efficacy
  • 12.5 ADXS11-001: Advaxis
    • 12.5.1 Product Description
    • 12.5.2 Product Development Activities
    • 12.5.3 Clinical Development
      • 12.5.3.1 Clinical Trial Information
  • 12.6 LN-145: Iovance Biotherapeutics
    • 12.6.1 Product Description
    • 12.6.2 Product Development Activities
    • 12.6.3 Clinical Development
      • 12.6.3.1 Clinical Trial Information
    • 12.6.4 Safety and Efficacy

13 Other Promising Therapies

  • 13.1 Balstilimab + Zalifrelimab: Agenus
    • 13.1.1 Product Description
    • 13.1.2 Product Development Activities
    • 13.1.3 Clinical Development
      • 13.1.3.1 Clinical Trial Information
    • 13.1.4 Safety and Efficacy
  • 13.2 Tiragolumab: Roche
    • 13.2.1 Product Description
  • 13.3 AK104: Akeso Biopharma
    • 13.3.1 Product Description
  • 13.4 Trastuzumab Deruxtecan: AstraZeneca
    • 13.4.1 Product Description
  • 13.5 VB10.16 + Atezolizumab: Vaccibody/ Roche
    • 13.5.1 Product Description
  • 13.6 RO6874281: Roche
    • 13.6.1 Product Description
  • 13.7 ALT 803: Altor BioScience
    • 13.7.1 Product Description
  • 13.8 Balstilimab: Agenus
    • 13.8.1 Product Description

14 Cervical Cancer: 7 Major Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Size of Cervical Cancer in 7MM
  • 14.3 Market Outlook - 7MM

15 Country-Wise Market Analysis

  • 15.1 The United States
    • 15.1.1 Total Market size of Cervical Cancer
    • 15.1.2 Cervical Cancer Market Size by Therapies
      • 15.1.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.1.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.1.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
  • 15.2 EU5 Countries
    • 15.2.1 Germany
      • 15.2.1.1 Total Market size of Cervical Cancer
      • 15.2.1.2 Cervical Cancer Market Size by Therapies
      • 15.2.1.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.2.1.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.2.1.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
    • 15.2.2 France
      • 15.2.2.1 Total Market size of Cervical Cancer
      • 15.2.2.2 Cervical Cancer Market Size by Therapies
      • 15.2.2.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.2.2.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.2.2.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
    • 15.2.3 Italy
      • 15.2.3.1 Total Market size of Cervical Cancer
      • 15.2.3.2 Cervical Cancer Market Size by Therapies
      • 15.2.3.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.2.3.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.2.3.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
    • 15.2.4 Spain
      • 15.2.4.1 Total Market size of Cervical Cancer
      • 15.2.4.2 Cervical Cancer Market Size by Therapies
      • 15.2.4.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.2.4.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.2.4.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
    • 15.2.5 The UK
      • 15.2.5.1 Total Market size of Cervical Cancer
      • 15.2.5.2 Cervical Cancer Market Size by Therapies
      • 15.2.5.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.2.5.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.2.5.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT
  • 15.3 Japan
    • 15.3.1 Total Market size of Cervical Cancer
    • 15.3.2 Cervical Cancer Market Size by Therapies
      • 15.3.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer
      • 15.3.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT
      • 15.3.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

16 Market Drivers

17 Market Barriers

18 Appendix

  • 18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

List of Tables

  • Table 1: Summary of Cervical Cancer Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total cases of Cervical Cancer in 7MM (2017-2030)
  • Table 3: Incident cases of Cervical Cancer in the United States (2017-2030)
  • Table 4: Stage Specific Incidence of Cervical Cancer in the United States(2017-2030)
  • Table 5: Histopathologic Types of Cervical Cancer in the United States(2017-2030)
  • Table 6: Age specific cases of Cervical Cancer in the United States(2017-2030)
  • Table 7: Incident cases of Cervical Cancer in Germany (2017-2030)
  • Table 8: Stage Specific Incidence of Cervical Cancer in Germany(2017-2030)
  • Table 9: Histopathologic Types of Cervical Cancer in Germany(2017-2030)
  • Table 10: Age specific cases of Cervical Cancer in Germany(2017-2030)
  • Table 11: Incident cases of Cervical Cancer in France (2017-2030)
  • Table 12: Stage Specific Incidence of Cervical Cancer in France(2017-2030)
  • Table 13: Histopathologic Types of Cervical Cancer in France(2017-2030)
  • Table 14: Age specific cases of Cervical Cancer in France(2017-2030)
  • Table 15: Incident cases of Cervical Cancer in Italy (2017-2030)
  • Table 16: Stage Specific Incidence of Cervical Cancer in Italy(2017-2030)
  • Table 17: Histopathologic Types of Cervical Cancer in Italy(2017-2030)
  • Table 18: Age specific cases of Cervical Cancer in Italy(2017-2030)
  • Table 19: Incident cases of Cervical Cancer in Spain (2017-2030)
  • Table 20: Stage Specific Incidence of Cervical Cancer in Spain(2017-2030)
  • Table 21: Histopathologic Types of Cervical Cancer in Spain(2017-2030)
  • Table 22: Age specific cases of Cervical Cancer in Spain(2017-2030)
  • Table 23: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)
  • Table 24: Stage Specific Incidence of Cervical Cancer in the United Kingdom(2017-2030)
  • Table 25: Histopathologic Types of Cervical Cancer in the United Kingdom(2017-2030)
  • Table 26: Age specific cases of Cervical Cancer in the United Kingdom(2017-2030)
  • Table 27: Incident cases of Cervical Cancer in Japan (2017-2030)
  • Table 28: Stage Specific Incidence of Cervical Cancer in Japan(2017-2030)
  • Table 29: Histopathologic Types of Cervical Cancer in Japan(2017-2030)
  • Table 30: Age specific cases of Cervical Cancer in Japan(2017-2030)
  • Table 31: Avastin, Clinical Trial Description, 2020
  • Table 32: Hycamtin, Clinical Trial Description, 2020
  • Table 33: Keytruda, Clinical Trial Description, 2020
  • Table 34: Tisotumab Vedotin , Clinical Trial Description, 2020
  • Table 35: Z-100, Clinical Trial Description, 2020
  • Table 36: Cemiplimab , Clinical Trial Description, 2020
  • Table 37: ADXS11-001, Clinical Trial Description, 2020
  • Table 38: LN-145 , Clinical Trial Description, 2020
  • Table 39: Balstilimab + Zalifrelimab, Clinical Trial Description, 2020
  • Table 40: 7 Major Market Size of Cervical Cancer in USD Million (2017-2030)
  • Table 41: The US Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 42: The US market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 43: The US market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 44: The US market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Table 45: Germany Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 46: Germany market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 47: Germany market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 48: Germany market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Table 49: France Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 50: France market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 51: France market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 52: France market size of Cervical Cancer by Therapies in USD Million (2017-2030)
  • Table 53: Italy Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 54: Italy market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 55: Italy market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 56: Italy market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Table 57: Spain Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 58: Spain market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 59: Spain market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 60: Spain market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Table 61: The UK Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 62: The UK market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 63: The UK market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 64: The UK market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Table 65: Japan Market size of Cervical Cancer in USD Million (2017-2030)
  • Table 66: Japan market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Table 67: Japan market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Table 68: Japan market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Terminology of cervical disease categories
  • Figure 3: Risk factors for cervical cancer
  • Figure 4: Risk factors for cervical cancer
  • Figure 5: Risk factors for cervical cancer
  • Figure 6: Timeline of public health research and policy of HPV and cervical cancer
  • Figure 7: Total Incident cases of Cervical Cancer in 7MM (2017-2030)
  • Figure 8: Incident cases of Cervical Cancer in the United States (2017-2030)
  • Figure 9: Stage Specific Incidence of Cervical Cancer in the United States (2017-2030)
  • Figure 10: Histopathologic Types of Cervical Cancer in the United States (2017-2030)
  • Figure 11: Age specific cases of Cervical Cancer in the United States (2017-2030)
  • Figure 12: Incident cases of Cervical Cancer in Germany (2017-2030)
  • Figure 13: Stage Specific Incidence of Cervical Cancer in Germany (2017-2030)
  • Figure 14: Histopathologic Types of Cervical Cancer in Germany (2017-2030)
  • Figure 15: Age specific cases of Cervical Cancer in Germany (2017-2030)
  • Figure 16: Incident cases of Cervical Cancer in France (2017-2030)
  • Figure 17: Stage Specific Incidence of Cervical Cancer in France (2017-2030)
  • Figure 18: Histopathologic Types of Cervical Cancer in France (2017-2030)
  • Figure 19: Age specific cases of Cervical Cancer in France (2017-2030)
  • Figure 20: Incident cases of Cervical Cancer in Italy (2017-2030)
  • Figure 21: Stage Specific Incidence of Cervical Cancer in Italy (2017-2030)
  • Figure 22: Histopathologic Types of Cervical Cancer in Italy (2017-2030)
  • Figure 23: Age specific cases of Cervical Cancer in Italy (2017-2030)
  • Figure 24: Incident cases of Cervical Cancer in Spain (2017-2030)
  • Figure 25: Stage Specific Incidence of Cervical Cancer in Spain (2017-2030)
  • Figure 26: Histopathologic Types of Cervical Cancer in Spain (2017-2030)
  • Figure 27: Age specific cases of Cervical Cancer in Spain (2017-2030)
  • Figure 28: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 29: Stage Specific Incidence of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 30: Histopathologic Types of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 31: Age specific cases of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 32: Incident cases of Cervical Cancer in Japan (2017-2030)
  • Figure 33: Stage Specific Incidence of Cervical Cancer in Japan (2017-2030)
  • Figure 34: Histopathologic Types of Cervical Cancer in Japan (2017-2030)
  • Figure 35: Age specific cases of Cervical Cancer in Japan (2017-2030)
  • Figure 36: Surgical treatment options for cervical cancer
  • Figure 37: Radiation treatment options for cervical cancer
  • Figure 38: Chemotherapy treatment options for cervical cancer
  • Figure 39: Workup for cervical cancer
  • Figure 40: Primary treatment for cervical cancer
  • Figure 41: Primary treatment for cervical cancer
  • Figure 42: Primary treatment for cervical cancer
  • Figure 43: Adjuvant treatment of cervical cancer
  • Figure 44: Patient Journey of Cervical Cancer
  • Figure 45: Unmet needs for cervical cancer
  • Figure 46: 7 Major Market Size of Cervical Cancer in USD Million (2017-2030)
  • Figure 47: Market Size of Cervical Cancer in the United States, USD Millions (2017-2030)
  • Figure 48: The U.S. market size for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 49: The U.S. market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 50: The U.S. market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Figure 51: Market Size of Cervical Cancer in Germany, USD Millions (2017-2030)
  • Figure 52: Germany market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 53: Germany market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 54: Germany market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Figure 55: Market Size of Cervical Cancer in France, USD Millions (2017-2030)
  • Figure 56: France market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 57: France market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 58: France market size of Cervical Cancer by therapies in USD Million (2017-2030)
  • Figure 59: Market Size of Cervical Cancer in Italy, USD Millions (2017-2030)
  • Figure 60: Italy market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 61: Italy market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 62: Italy market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Figure 63: Market Size of Cervical Cancer in Spain, USD Millions (2017-2030)
  • Figure 64: Spain market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 65: Spain market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 66: Spain market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Figure 67: Market Size of Cervical Cancer in the UK, USD Millions (2017-2030)
  • Figure 68: The U.K. market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 69: The U.K. market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 70: The U.K. market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Figure 71: Market Size of Cervical Cancer in Japan, USD Millions (2017-2030)
  • Figure 72: Japan market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017-2030)
  • Figure 73: Japan market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017-2030)
  • Figure 74: Japan market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017-2030)
  • Figure 75: Market drivers for Cervical cancer
  • Figure 76: Market Barriers for Cervical cancer
Back to Top